で公開中です! 詳しく見る
6.04 USD
-0.64
9.58%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
6.13
+0.09
1.49%
1日
-9.58%
5日間
-20.84%
1か月
-16.23%
3か月
20.8%
6か月
30.17%
年初来
87%
1年
51.38%
5年間
-93.95%
10年間
-94.75%
 

概要: Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

従業員数: 81

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 0%
ニュートラル 93.3%
ネガティブ 6.7%
ニュートラル
Business Wire
7 日前
Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor meetings at Chardan's 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation, on October 20, 2026. Chardan 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation Date: Tuesday, October 20, 2026 Location:.
Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
ニュートラル
Business Wire
8 日前
Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases who have previously received ava.
Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
ニュートラル
Business Wire
13 日前
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus' multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus' anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by.
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
ニュートラル
Business Wire
14 日前
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona. The clinical poster will review the featur.
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
ニュートラル
Seeking Alpha
先月
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
ニュートラル
Business Wire
先月
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada. The presentation will feature results from the recurre.
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
ニュートラル
Business Wire
先月
Agenus to Participate in Upcoming September Investor Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor conferences in September. Cantor Global Healthcare Conference 2026 September 9 -11, 2026; New York, NY Fireside Chat: Tuesday, September 8, 2026 | 11:30 a.m-12:00 p.
Agenus to Participate in Upcoming September Investor Conferences
ニュートラル
Business Wire
先月
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in 123 heavily pre-treated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The manuscript,.
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
ニュートラル
Business Wire
先月
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus' multifunctional, Fc-enhanced anti-CTLA-4 antibody, and balstilimab (BAL), Agenus' anti-PD-1 antibody, in patients with resectable colon cancer. The manuscript, titled “Neoadjuvant botensilimab/balstilimab for localized mismatch r.
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
ネガティブ
Zacks Investment Research
2 か月前
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
Agenus (AGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $1 per share a year ago.
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
価格チャートは Lightweight Charts™ を使用して実装されています